Tolerance Bio and ZipCode Bio have launched a strategic research-and-development collaboration to explore novel delivery methods for thymus-targeted therapeutics, according to the companies. The alliance combines Tolerance Bio’s expertise in thymus biology and immunology with ZipCode Bio’s SHARP (Single-component Homogeneous Amphiphilic Routed Particles) RNA delivery platform.
The partnership will focus initially on preclinical development of precision therapeutics intended to preserve, restore or manipulate thymic function in the context of immune-mediated diseases and immune aging. ZipCode Bio will lead development of thymus-targeting SHARPs, while Tolerance Bio will drive translation into disease models.
Tolerance Bio, launched in 2024 by former Provention Bio and Semma executives, is building a multi-modality platform aimed at modifying immune tolerance via the thymus. ZipCode Bio, co-founded by Nobel Laureate Dr. Drew Weissman, applies next-generation RNA delivery technologies designed for improved safety, efficacy and streamlined manufacturing, and leverages machine learning tools to accelerate therapeutic design.
According to the companies, the collaboration pools complementary strengths in thymus biology and RNA delivery to pursue new therapeutic possibilities for patients affected by immune aging and dysregulation.
